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مرض كوشنج بسبب زيادة إفراز اهلرمون املوجِّه لقشر الكظر
ه لق�رض الكظر من الغدة النخامية أم من خارجها استعمال أوكرتيوتايد ملعرفة مصدر زيادة إفراز الهرمون املوِجّ
اأميمة ال�ضفيع، نورالدين ال�ضايف، أحمد ال�ضجواين، نيكوال�س وود هو�س
abstract: Objectives: Adrenocorticotropic hormone (ACTH) overproduction is usually due to a pituitary 
tumour which is often not visible on magnetic resonance imaging (MRI). However, ACTH overproduction may 
be due to an ectopic source. This study aimed to develop a simple non-invasive technique to differentiate these 
sources. Methods: This study took place in King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi 
Arabia, and Sultan Qaboos University Hospital, Muscat, Oman, between 1988 and 2012. Serum cortisol levels 
were measured in nine patients with ACTH-dependent Cushing’s syndrome before and during a 72-hour trial of 
octreotide. All patients underwent computed tomography (CT) scans. MRI scans were performed on six patients. 
Results: CT scans were abnormal in three patients with ectopic ACTH production. MRI scans showed that three 
patients had pituitary microadenomas. Serum cortisol levels returned to normal in those with confirmed ectopic 
ACTH production. No response was found in the other six patients. Conclusion: A 72-hour trial of octreotide is 
recommended for patients with ACTH-dependent Cushing’s syndrome and a normal pituitary MRI. This trial will 
be a useful alternative to petrosal sinus sampling.
Keywords: Adrenocorticotrophic Hormone; Cushing’s Syndrome; Somatostatin Receptors; Investigational Therapies; 
Octreotide; Saudi Arabia; Oman.
ه لق�رض الكظر )ACTH( امل�ضبب ملر�س كو�ضنج غالبا ما يكون ب�ضبب ورم �ضغري يف الغدة  امللخ�ص: الهدف: اإن زيادة اإفراز الهرمون املوِجّ
النخامية ويف معظم االأحيان ال ميكن حتديد الورم باأ�ضعة الرنني املغناطي�ضي، كما اأن اإفراز هذا الهرمون قد يكون ب�ضبب ورم خارج الغدة 
النخامية. الغر�س من هذه الدرا�ضة هو تو�ضيح طريقة ب�ضيطة يتم من خللها معرفة م�ضدر الزيادة يف اإفراز هرمون)ACTH( ما اإذا كان 
من الغدة النخامية اأو مكان اآخر يف اجل�ضم. الطريقة: متت هذه الدرا�ضة يف م�ضت�ضفى امللك في�ضل التخ�ض�ضي ومركز االأبحاث، الريا�س، 
اململكة العربية ال�ضعودية، وم�ضت�ضفى جامعة ال�ضلطان قابو�س، م�ضقط، �ضلطنة عمان، بني عامي 1988 و 2102م. متت الدرا�ضة على ت�ضع 
مر�ضى يعانون من مر�س كو�ضنج ب�ضبب زيادة اإفراز هرمون اي.�ضي.تي.ايج حيث قمنا مبراقبة م�ضتوى هرمون الكورتيزول يف الدم قبل 
اأ�ضعة مقطعية جلميع املر�ضى الت�ضعة و اأجري فح�س الرنني املغناطي�ضي على  وخلل 72 �ضاعة من بدء العلج باالوكرتيوتايد. مت اأخذ 
�ضتة مر�ضى. النتائج: كانت نتائج االأ�ضعة املقطعية غري طبيعية يف ثلثة من املر�ضى الذين كانوا م�ضابني باأورام خارج الغدة النخامية. 
اإىل  اأن ثلثة من املر�ضى لديهم ورم �ضغري يف الغدة النخامية.  انخف�س م�ضتوى هرمون الكورتزول  اأظهرت نتائج الرنني املغناطي�ضي 
الطبيعي عند املر�ضى الذين كانوا م�ضابني باأورام خارج الغدة النخامية اأما املر�ضى الستة الباقني فإن م�ضتوى الكورتزول بقي مرتفعا. 
اخلال�صة: نن�ضح با�ضتعمال االوكرتيوتايد ملدة 72 �ضاعة مع كل مر�ضى كو�ضنج ب�ضبب زيادة اإفراز هرمون اي.�ضي.تي.ايج والذين تكون 
هرمون  قيا�س  عن  كبديل  للت�ضخي�س  الطريقة  هذه  ا�ضتعمال  ميكن  أنه  كما  لديهم،  طبيعية  النخامية  للغدة  املغناطي�ضي  الرنني  نتيجة 
)ACTH( عن طريق �ضحب عينات الدم من داخل اأوردة اجلمجمة.




Use of an octreotide trial to distinguish between pituitary or ectopic sources
*Omayma T. El-Shafie,1 Nooralddin Al-Saffi,1 Ahmed Al-Sajwani,2 Nicholas Woodhouse3
The most common cause of adreno-corticotropic hormone (ACTH)-dependent Cushing’s syndrome is a pituitary adenoma 
(90%).1 When this cause is identified, the condition 
is also known as Cushing’s disease. Other cases of 
ACTH-dependent Cushing’s syndrome are due to 
ectopic ACTH secretion, generally by bronchial 
or pancreatic neuroendocrine tumours (NETs) or, 
rarely, tumours that secrete corticotropin-releasing 
hormone (CRH).2 However, in 40% of patients with 
Cushing’s disease, magnetic resonance imaging 
(MRI) shows a normal pituitary gland.3 These patients 
must be distinguished from those with ectopic 
ACTH production. The gold-standard practice 
for differentiating pituitary from ectopic ACTH 
overproduction is performing inferior petrosal sinus 
sampling (IPSS) with serial ACTH measurements after 
the intravenous administration of CRH. This procedure 
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necessitates the cannulation of both jugular veins and 
is therefore invasive and costly.4 As a result, the Sultan 
Qaboos University Hospital (SQUH), a tertiary centre 
in Muscat, Oman, relies on indirect testing to confirm 
or refute the pituitary source. As most NETs express 
somatostatin receptors type 2 and 3, they are therefore 
amenable to treatment with octreotide which lowers 
ACTH and cortisol levels.5–7 Patients with Cushing’s 
disease do not respond to octreotide due to the 
lack of expression or downregulation of somatostatin 
receptors.8 Furthermore, patients with NETs secrete 
chromogranin A (Cg-A) as well; it has therefore been 
theorised that the measurement of Cg-A levels may 
prove to be of additional diagnostic value.9 In light of 
these factors, and because IPSS is not available in all 
centres, the objective of this study was to test the use 
of a 72-hour trial of octreotide to distinguish between 
pituitary and ectopic ACTH overprodu ction.
Methods
This study took place in King Faisal Specialist Hospital 
& Research Centre, Riyadh, Saudi Arabia, and SQUH 
between 1988 and 2012. Nine patients with ACTH-
dependent Cushing’s syndrome confirmed by elevated 
fasting serum cortisol and ACTH levels were included 
in the study. Four of these patients have previously been 
reported in the literature.5 Computed tomography 
(CT) scans of the neck, chest and abdomen were 
carried out on all patients. In addition, six patients 
underwent MRI scans and two had their Cg-A levels 
measured on admission after fasting. Each patient 
undertook a 72-hour therapeutic trial of octreotide, 
with a dose of 100 mcg administered every eight 
hours. Serial cortisol measurements were taken at the 
beginning of the trial (8 am) and then subsequently 
24, 48 and 72 hours after the trial had begun. Some 
patients had basal samples taken 48 and 24 hours 
before the trial began.
Subjects whose serum cortisol levels were 
unchanged throughout the study period were 
determined not to have responded to the octreotide 
trial, while patients whose serum cortisol levels 
decreased to within a normal range were determined 
to have responded to the treatment. All patients 
and their families gave consent for their inclusion in 
the study. 
Results
A total of nine patients with ACTH-dependent 
Cushing’s syndrome were identified during the study 
period. Serum cortisol levels were unchanged in six 
patients but fell progressively to normal levels in the 
remaining three patients [Figure 1]. The six subjects 
who did not respond to the octreotide trial had 
normal CT results of the neck, chest and abdomen. 
In comparison, the patients who responded to the 
treatment had abnormal CT scans of the lung and 
pancreas. Cg-A levels were normal in the two patients 
who did not respond. Of the six patients who did 
not respond to the octreotide, MRI scans revealed 
pituitary microadenomas in three, while the other 
three patients had normal MRI results.
Among the three subjects who responded to 
octreotide, NETs were identified as the source of 
the ACTH overproduction. Before the trial started, 
one of the three patients was documented to have a 
benign bronchial carcinoid tumour while the other 
two were identified as having metastatic pancreatic 
NETs producing ACTH both radiologically and 
histologically. The first patient had no need for 
further treatment following the removal of the benign 
bronchial carcinoid tumour. The other two patients 
died within a year of diagnosis. 
For the six patients who did not respond to 
octeotride, pituitary adenomas (Cushing’s disease) 
were identified as the source of the ACTH over-
production. Of these, five underwent transsphenoidal 
surgeries (TSS) [Table 1]. Two patients were cured after 
their surgeries, while another two relapsed initially but 
at the time of writing were both in complete remission 
and receiving cabergoline treatment. One patient 
relapsed and received external radiotherapy; after this, 
the patient went abroad and was lost to follow up. At 
the time of writing, the final patient was in complete 
remission and was receiving cabergoline therapy 
without any other interventions.
 
Figure 1: Serum cortisol levels in nine patients with 
adrenocorticotropic hormone-dependent Cushing’s 
syndrome before and during a trial of octreotide. 
Only three patients, all of whom were found to have 
neuroendocrine tumours, responded to treatment.
Grey bar = normal cortisol levels.
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Discussion
ACTH-dependent Cushing’s syndrome is rare and 
usually caused by a pituitary adenoma; however, 10% 
of cases are ectopic.1,2 If the source of the ACTH 
overproduction is not readily apparent, centres with 
the necessary resources can carry out IPSS with 
ACTH measurements. This procedure will distinguish 
pituitary from ectopic sources and help localise 
the site of the tumour within the pituitary gland. 
However, as IPSS is not yet available in all centres, it 
is important to develop alternative approaches. One 
such approach consists of a short trial of octreotide, 
which has been assessed and reported previously.5 As 
shown in the current study, only three patients with 
ACTH-dependent Cushing’s syndrome were found to 
have decreased cortisol levels and therefore to have 
responded to the octreotide treatment; these patients 
were subsequently found to have NETs. In comparison, 
there was no response in the remaining six patients 
who were diagnosed with Cushing’s disease. 
Somatostatin receptors are expressed in normal 
pituitary ACTH-producing cells; however, it has been 
found that the expression of somatostatin receptors 
2 and 3 is downregulated by elevated glucocorticoid 
levels.8 This explains why octreotide is not 
therapeutically useful in Cushing’s disease. A study by 
de Herder et al. using somatostatin receptor imaging 
further supports the results of the present study, as 
octreotide scanning was negative in eight patients 
with ACTH-secreting pituitary adenomas whereas 
uptake was positive in all 10 of their patients identified 
with NETs producing ectopic ACTH.9
Most NETs co-secrete Cg-A with hormones;10 
thus, the measurement of circulating Cg-A levels 
was recently added to the octreotide trial procedure 
reported in the current study. This measurement was 
included as a further diagnostic tool to distinguish 
pituitary from ectopic disease. This combination is 
currently carried out routinely in SQUH. 
In another recent study conducted in Oman, high-
dose cabergoline was used successfully to treat four 
patients with Cushing’s disease.11 Although one of 
the patients refused surgery, they were treated with 
cabergoline monotherapy; the dosage was reduced 
from 1 mg/day to 1 mg twice weekly and the patient 
has remained in complete remission for almost three 
years since the time of writing.11 As a result of these 
observations, the current practice at SQUH is to offer a 
short-term trial of cabergoline to patients with ACTH-
dependent Cushing’s syndrome who do not respond to 
octreotide and have normal pituitary MRIs. If the patient 
responds, they may be offered long-term cabergoline 
treatment or a laparoscopic adrenalectomy. Should the 
patient subsequently develop Nelson’s syndrome, a TSS 
may then be carried out.12
Conclusion
The results of this study indicate that a 72-hour trial 
of octreotide is advisable for all patients with ACTH-
dependent Cushing’s syndrome and normal MRI 
results. This procedure has been shown to be a safe 
and simple method that will effectively distinguish 
between pituitary and ectopic ACTH overproduction. 
In addition, it is a useful alternative to IPSS in centres 
where this procedure is not available.
Table 1: Fasting serum cortisol and ACTH levels and imaging results in nine patients with ACTH-induced Cushing’s 
syndrome at presentation and subsequently identified source of ACTH overproduction




CT/MRI TSS Source 
1 675 25 - - Ectopic (lung carcinoid)
2 826 9 - - Ectopic (pancreatic carcinoid)
3 856 27 - - Ectopic (pancreatic carcinoid)
4 612 13 Normal Performed Pituitary
5 812 4 Normal Performed Pituitary
6 752 14 Normal Not perfomed Pituitary
7 923 24 Microadenoma Perfomed Pituitary
8 700 16 Microadenoma Performed Pituitary
9 1,100 6 Microadenoma Performed Pituitary
ACTH = adrenocorticotropic hormone; Cg-A = chromogranin A; CT = computed tomography; MRI = magnetic resonance imaging; TSS = transsphenoidal 
surgery. *Normal range: 184–580 nmol/L; **Normal range: 1.6–13.9 pmol/L.
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